Notice of Participation of the National Institute on Drug Abuse(NIDA) in RFA-MD-21-001, "Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)"
Notice Number:

Key Dates

Release Date:

November 12, 2020

Related Announcements

RFA-MD-21-001 - Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)


The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) is participating, effective immediately, in RFA-MD-21-001, "Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional)"."

The following text has been added to reflect NIDA's participation in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)


Part 2. Section I. Funding Opportunity Description

NIDA is interested in supporting research involving people who use drugs (PWUD) including members of key populations among whom drug use is a common contributing risk to HIV acquisition: gay, bisexual, and other men who have sex with men (MSM), Transgender Persons, Sex Workers, and High Risk Heterosexuals (HRH). Outside of drug use, populations should conform to the criteria for highest risk based on available evidence outlined in the RFA (including incorporation of jurisdictions included in the Ending the HIV Epidemic initiative) and efforts should be made to incorporate members of these populations as active contributors to intervention development and implementation.

Areas of special interest include but are not limited to the following:

  • Multi-level interventions that incorporate substance use treatment, harm reduction or other settings that commonly provide substance use services.
  • Interventions that directly engage sexual partners and/or drug use (injecting and non-injecting) partners in HIV risk reduction.
  • Structural interventions to reduce HIV acquisition that incorporate improved access to substance use prevention, treatment and harm reduction.
  • Interventions that include provider or organization-level components to enhance cultural competency and reduce health-care related stigma and discrimination towards PWUD, particularly those who are members of racial/ethnic minorities, and/or sexual and gender minorities.
  • Multi-level interventions that incorporate outreach to novel settings with the capacity to engage difficult-to-reach populations of PWUD or key populations where drug use is common.
  • Interventions that address HIV prevention and drug use in the context of addressing comorbidities such as intimate partner violence, marginal housing or serious mental disorder.
  • Collaboration with diverse local organizations and stakeholders such as drug use prevention programs, public health and social service outreach, substance use treatment settings, school systems, justice settings, community-based organizations, population advocacy organizations, and faith-based organizations.
  • Projects that incorporate novel approaches to PrEP delivery such as same day PrEP outside of clinic settings.
  • Projects that incorporate cost-effectiveness of intervention implementation and delivery.

Part 2. Section II, Award Information

Funds Available and Anticipated Number of Awards

NIDA intends to commit $1M in FY2021 to fund 2 awards.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Richard A. Jenkins, PhD
National Institute on Drug Abuse (NIDA)

Financial/Grants Management Contact(s)
 Pam Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-1159

All other aspects of the FOA remain the same.


Please direct all inquiries to:

Richard A. Jenkins
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices